[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies in Neurology
August 2001

Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis

Author Affiliations

From the Department of Neurosciences, University of Medicine and Dentistry of New Jersey Medical School, Newark.



Arch Neurol. 2001;58(8):1299-1300. doi:10.1001/archneur.58.8.1299

THE NEUROLOGIST, like an Argonaut in his search for the Golden Fleece, has through the years been doggedly trying to achieve his lofty goal of optimally treating his or her patients with multiple sclerosis (MS). Progress has been made. A recombinant cytokine, interferon beta (administered as Betaseron or Avonex), has been widely used in the past decade and is the first recombinant protein extensively prescribed by neurologists. It is thus a "pioneer" therapy from which we all need to learn as much as possible before the next recombinant protein is available.

First Page Preview View Large
First page PDF preview
First page PDF preview